Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viromed Medical AGFRA:VME -2.75%22 Equity-to-Asset is 0.75 as of Dec. 2025, which is 23% below its 10-year median of 0.98. GuruFocus rates FRA:VME with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 851 Medical Devices & Instruments companies, Viromed Medical AG ranks better than 68.04% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Viromed Medical AG's Total Stockholders Equity for the quarter that ended in Dec. 2025 was €10.47 Mil. Viromed Medical AG's Total Assets for the quarter that ended in Dec. 2025 was €13.91 Mil.
Therefore, Viromed Medical AG's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.75.
The historical rank and industry rank for Viromed Medical AG's Equity-to-Asset or its related term are showing as below:
FRA:VME'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.69 Med: 0.98 Max: 0.99
Current: 0.75
During the past 5 years, the highest Equity to Asset Ratio of Viromed Medical AG was 0.99. The lowest was 0.69. And the median was 0.98.
FRA:VME's Equity-to-Asset is ranked better than 68.04% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs FRA:VME: 0.75
Viromed Medical AG (FRA:VME) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Viromed Medical AG Equity-to-Asset Related Terms
Viromed Medical AG Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Viromed Medical AG's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VME vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, Viromed Medical AG's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viromed Medical AG Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Viromed Medical AG's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Viromed Medical AG's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Viromed Medical AG's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viromed Medical AG (FRA:VME) has a Equity-to-Asset of 0.75 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Viromed Medical AG and its competitors. This is 23% below median its historical median of 0.98. Over the past decade, Viromed Medical AG's Equity-to-Asset has ranged from 0.69 to 0.99. According to the industry distribution chart, Viromed Medical AG ranks #272 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 32%.
Is Viromed Medical AG's Equity-to-Asset too high?
Viromed Medical AG's current Equity-to-Asset of 0.75 is 23% below median its 10-year median of 0.98. Over the past 10 years, this metric has ranged from a low of 0.69 to a high of 0.99. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Viromed Medical AG's value of 0.75 is 17.2% above this industry median. Based on the distribution chart, Viromed Medical AG ranks #272 out of 851 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Viromed Medical AG has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Viromed Medical AG's Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Viromed Medical AG ranks #272 out of 851 companies for Equity-to-Asset. This puts Viromed Medical AG in the upper half of its industry. The industry median Equity-to-Asset is 0.64. Viromed Medical AG's value of 0.75 is 17.2% above this benchmark. Historically, Viromed Medical AG's own Equity-to-Asset has ranged from 0.69 to 0.99 over the past decade. While the company's 10-year median is 0.98 vs. the industry median of 0.64, Viromed Medical AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viromed Medical AG's current Equity-to-Asset of 0.75 is 17.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Viromed Medical AG and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viromed Medical AG's current Equity-to-Asset is 0.75, which is 23% below median its own 10-year median of 0.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viromed Medical AG stock overvalued right now?
Viromed Medical AG (FRA:VME) has a current Equity-to-Asset of 0.75. The current Equity-to-Asset is 0.75, which is 23% below median its 10-year median of 0.98 and 17.2% above the Medical Devices & Instruments industry median of 0.64. Viromed Medical AG's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Viromed Medical AG (FRA:VME), the current Equity-to-Asset is 0.75 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Viromed Medical AG is a medical technology company. It focuses on using cold plasma technology to develop medical solutions that protect people from viruses, bacteria, and multi-resistant germs. Viromed's product offerings include ViroCAP, a medical device based on cold plasma technology for treating wounds; ViroCAP derma-podo, a medical device that uses cold atmospheric plasma therapy for skin and foot care; and a Raumluftentkeimer. The company covers the entire value chain from research and development to production, logistics, marketing, and sales of its products.
22GF Score
Get the complete analysis for FRA:VME
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VME has been successfully added to your 
